It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Effective drug delivery is restricted by pathophysiological barriers in solid tumors. In human pancreatic adenocarcinoma, poorly-permeable blood vessels limit the intratumoral permeation and penetration of chemo or nanotherapeutic drugs. New and clinically viable strategies are urgently sought to breach the neoplastic barriers that prevent effective drug delivery. Here, we present an original idea to boost drug delivery by selectively knocking down the tumor vascular barrier in a human pancreatic cancer model. Clinical radiation activates the tumor endothelial-targeted gold nanoparticles to induce a physical vascular damage due to the high photoelectric interactions. Active modulation of these tumor neovessels lead to distinct changes in tumor vascular permeability. Noninvasive MRI and fluorescence studies, using a short-circulating nanocarrier with MR-sensitive gadolinium and a long-circulating nanocarrier with fluorescence-sensitive nearinfrared dye, demonstrate more than two-fold increase in nanodrug delivery, post tumor vascular modulation. Functional changes in altered tumor blood vessels and its downstream parameters, particularly, changes in Ktrans (permeability), Kep (flux rate), and Ve (extracellular interstitial volume), reflect changes that relate to augmented drug delivery. The proposed dual-targeted therapy effectively invades the tumor vascular barrier and improve nanodrug delivery in a human pancreatic tumor model and it may also be applied to other nonresectable, intransigent tumors that barely respond to standard drug therapies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Brigham and Women’s Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Department of Radiation Oncology, Boston, United States (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294)
2 Brigham and Women’s Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Department of Radiation Oncology, Boston, United States (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); Université Claude Bernard Lyon 1, CNRS, Institut Lumière Matière, UMR 5306, Villeurbanne, France (GRID:grid.7849.2) (ISNI:0000 0001 2150 7757)
3 Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague 6, Czech Republic (GRID:grid.424999.b) (ISNI:0000 0001 0667 6325)
4 Brigham and Women’s Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Department of Radiation Oncology, Boston, United States (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); Northeastern University, Nanomedicine Science and Technology Center and Department of Physics, Boston, United States (GRID:grid.261112.7) (ISNI:0000 0001 2173 3359)
5 Northeastern University, Nanomedicine Science and Technology Center and Department of Physics, Boston, United States (GRID:grid.261112.7) (ISNI:0000 0001 2173 3359)
6 University Hospital and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Experimental Molecular Imaging, Aachen, Germany (GRID:grid.1957.a) (ISNI:0000 0001 0728 696X)
7 University of Texas Southwestern Medical Center, Division of Medical Physics & Engineering, Texas, United States (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
8 Université Claude Bernard Lyon 1, CNRS, Institut Lumière Matière, UMR 5306, Villeurbanne, France (GRID:grid.7849.2) (ISNI:0000 0001 2150 7757)
9 Institute for Advanced Biosciences, UGA/INSERM U1209/CNRS UMR 5309 Joint Research Center, Grenoble, France (GRID:grid.418110.d) (ISNI:0000 0004 0642 0153)
10 Dana-Farber Cancer Institute and Harvard Medical School, Lurie Family Imaging Center, Department of Radiology, Boston, United States (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
11 Boston University, LA-ICP-MS and ICP-ES Laboratories, Department of Earth and Environmental Sciences, Boston, United States (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558)